secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001650664-24-000141
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas halts reni-cel, cuts 65% workforce, shifts to in vivo gene editing
-------------------------------------------------------------------------

- Discontinues ex vivo reni-cel program for sickle cell and beta thalassemia; ends partnering process.
- Reduces workforce by ~180 positions (65%); costs of $55-70M for discontinuation, $14-18M for reduction.
- Cash runway extended to Q2 2027; focuses on in vivo pipeline, with human proof-of-concept target in ~2 years.
- CMO Baisong Mei steps down Dec 31; board members Emma Reeve and Meeta Chatterjee resign; Jessica Hopfield becomes Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/0001650664-24-000141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/edit-20241211.htm
  HTML page:      https://secwatch.observer/filing/0001650664-24-000141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer